IN2013MN00441A - - Google Patents

Info

Publication number
IN2013MN00441A
IN2013MN00441A IN441MUN2013A IN2013MN00441A IN 2013MN00441 A IN2013MN00441 A IN 2013MN00441A IN 441MUN2013 A IN441MUN2013 A IN 441MUN2013A IN 2013MN00441 A IN2013MN00441 A IN 2013MN00441A
Authority
IN
India
Prior art keywords
peptide
keratin
glucagon
type
assays
Prior art date
Application number
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of IN2013MN00441A publication Critical patent/IN2013MN00441A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta nerve growth factor Interleukin 17A Follitropin subunit beta Collagenase 3 Follistatin Vitamin D Binding Protein Islet amyloid polypeptide Insulin C peptide Complement Factor H Gastric inhibitory polypeptide Glucagon like peptide 1 Glucagon Involucrin Type II cytoskeletal Keratin 1/Keratin 10 Type II cytoskeletal Keratin 6 A/6B/6C Osteocalcin Lipopolysaccharide Pancreatic prohormone Peptide YY Agouti related protein Ciliary neurotrophic factor Appetite regulating hormone Transthyretin Insulin receptor substrate 1 and NF kappa B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries.
IN441MUN2013 2010-10-07 2011-10-06 IN2013MN00441A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39099910P 2010-10-07 2010-10-07
PCT/US2011/055055 WO2012048082A2 (en) 2010-10-07 2011-10-06 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
IN2013MN00441A true IN2013MN00441A (en) 2015-05-29

Family

ID=45928428

Family Applications (1)

Application Number Title Priority Date Filing Date
IN441MUN2013 IN2013MN00441A (en) 2010-10-07 2011-10-06

Country Status (12)

Country Link
US (1) US20130316370A1 (en)
EP (2) EP2625524A4 (en)
JP (3) JP2013539861A (en)
CN (1) CN103238068B (en)
AU (1) AU2011311997A1 (en)
CA (1) CA2811438A1 (en)
EA (1) EA201390293A1 (en)
HK (1) HK1186248A1 (en)
IN (1) IN2013MN00441A (en)
MX (1) MX2013003662A (en)
NZ (1) NZ608316A (en)
WO (1) WO2012048082A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015042465A1 (en) * 2013-09-20 2015-03-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
EP3108259B1 (en) * 2014-02-20 2018-12-05 Immundiagnostik AG In vitro diagnostic and prognosis of contrast induced nephropathy (cin) in patients undergoing coronary angiography
CN107709993A (en) * 2015-06-11 2018-02-16 阿斯图特医药公司 Method and composition for diagnosis and the prognosis of injury of kidney and kidney failure
CN106405064B (en) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 A kind of appraisal procedure of 40 years old or more women bone turnover rate
WO2018165936A1 (en) * 2017-03-16 2018-09-20 深圳先进技术研究院 Polypeptide for regulating energy metabolism and uses thereof
CN109468357A (en) * 2018-12-25 2019-03-15 河北肽都生物科技有限公司 A kind of preparation method of spleen aminopeptide
CN114269722A (en) * 2019-07-26 2022-04-01 贝尔维奇生物医学研究所(伊迪贝尔) Ergothioneine, S-methyl-ergothioneine and uses thereof
CN113092768A (en) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 Application of urine keratin, II type cytoskeleton 1 and polypeptide fragment thereof in allergic diseases
CN114264828B (en) * 2022-01-28 2023-09-08 中国科学院基础医学与肿瘤研究所(筹) Biomarker for identifying benign thyroid nodule and thyroid cancer and application thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
AU658374B2 (en) 1990-09-14 1995-04-13 Biosite Diagnostics Incorporated Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
WO1992018866A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP4487376B2 (en) * 2000-03-31 2010-06-23 味の素株式会社 Kidney disease treatment
JP2002191398A (en) * 2000-12-26 2002-07-09 Jenokkusu Soyaku Kenkyusho:Kk Method for examining allergic disease
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US6941172B2 (en) * 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
WO2005100593A1 (en) * 2004-04-16 2005-10-27 Monash University A method for monitoring the progress of cancer
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
FR2872579B1 (en) * 2004-06-30 2006-11-24 Pasteur Institut DETECTION OF TUBERCULOSIS AND MYCOBACTERIUM TUBERCULOSIS INFECTION USING HBHA
CN101299962A (en) * 2004-12-15 2008-11-05 貝丝以色列女执事医疗中心 Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
DK2128625T3 (en) * 2004-12-20 2017-05-01 Antibodyshop As Determination of neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic marker for renal disorders
US20070087387A1 (en) * 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
JP2007057509A (en) * 2005-08-26 2007-03-08 Toray Ind Inc Method of measuring cat activin a, and measuring kit
WO2007106781A2 (en) * 2006-03-10 2007-09-20 University Of Rochester Ecg-based differentiation of lqt1 and lqt2 mutation
WO2007109809A1 (en) * 2006-03-23 2007-09-27 Invitrogen Corporation Methods and reagents for in vivo imaging of cancer cell lines
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
DK2125899T3 (en) * 2007-03-26 2013-02-11 Novartis Ag Biomarkers for predicting renal safety as well as biomarker signatures for monitoring renal function
US9091695B2 (en) * 2007-06-01 2015-07-28 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
US8039227B2 (en) * 2007-09-20 2011-10-18 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
WO2010057184A2 (en) * 2008-11-17 2010-05-20 The Brigham And Women's Hospital, Inc. Methods for detection of acute kidney injury in humans
BRPI0921921A2 (en) * 2008-11-22 2019-09-24 Astute Medical Inc method for assessing renal condition in an individual; and, use of one or more markers of renal injury.
CN102597258B (en) * 2009-02-06 2016-02-17 阿斯图特医药公司 The diagnosis and prognostic of injury of the kidney and renal failure
AU2010210540B2 (en) * 2009-02-06 2015-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and failure
CA2790785A1 (en) * 2010-02-26 2011-09-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
JP2016180762A (en) 2016-10-13
US20130316370A1 (en) 2013-11-28
CN103238068A (en) 2013-08-07
WO2012048082A2 (en) 2012-04-12
JP6321080B2 (en) 2018-05-09
AU2011311997A1 (en) 2013-04-04
JP2013539861A (en) 2013-10-28
MX2013003662A (en) 2013-05-01
EA201390293A1 (en) 2013-09-30
NZ608316A (en) 2015-03-27
JP2018141793A (en) 2018-09-13
CN103238068B (en) 2016-06-08
CA2811438A1 (en) 2012-04-12
EP3249402A1 (en) 2017-11-29
WO2012048082A3 (en) 2012-06-21
HK1186248A1 (en) 2014-03-07
EP2625524A4 (en) 2014-05-07
EP2625524A2 (en) 2013-08-14

Similar Documents

Publication Publication Date Title
IN2013MN00441A (en)
Diedisheim et al. Modeling human pancreatic beta cell dedifferentiation
Hackett et al. The human airway epithelial basal cell transcriptome
Atkinson et al. C9ORF72 expression and cellular localization over mouse development
Li et al. Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand
Kuo et al. Induction of α cell–restricted Gc in dedifferentiating β cells contributes to stress-induced β cell dysfunction
MX2011004767A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
WO2008060607A3 (en) Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
Camilleri et al. Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion
WO2008076262A3 (en) Receptor for amyloid beta and uses thereof
Dobarro et al. Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
MX2009012531A (en) Methods and compositions for identifying and treating lupus.
Yamane et al. Mechanisms of fat‐induced gastric inhibitory polypeptide/glucose‐dependent insulinotropic polypeptide secretion from K cells
WO2009101181A3 (en) Plasma membrane biomarkers preferentially expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2009101059A3 (en) Methods of using cadherin 11 (cdh11) antagonists
WO2009019365A3 (en) Ezrin assay method for the in vitro diagnosis of colorectal cancer
BR112013021056A2 (en) monoclonal antibody, hybridoma cell line, diagnostic kit, methods for producing a monoclonal antibody and binding agent, purified amino acid sequence binding agent, method for obtaining a coding nucleic acid sequence, antibody molecule encoding isolated nucleic acid, vector, isolated host cell, fusion protein, screening method for the presence of a disease, a condition, methods of diagnosing an individual, prognosis for an individual, and monitoring an individual, and , method for detecting the presence or absence of cervical cancer
Auinger et al. Human intestinal fatty acid binding protein 2 expression is associated with fat intake and polymorphisms
Oppenländer et al. Vertical sleeve gastrectomy triggers fast β-cell recovery upon overt diabetes
Loyd et al. LDB1 regulates energy homeostasis during diet-induced obesity
Canivell et al. Gastric inhibitory polypeptide receptor methylation in newly diagnosed, drug-naive patients with type 2 diabetes: a case-control study
Cendrowski et al. Mnk1 is a novel acinar cell-specific kinase required for exocrine pancreatic secretion and response to pancreatitis in mice
WO2008088836A3 (en) Compositions and methods for treatment of colorectal cancer